|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
MapLight Therapeutics, Inc. (Name of Issuer) |
Common Stock, $0.0001 par value per share (Title of Class of Securities) |
(CUSIP Number) |
Robert Brown c/o Catalyst4, Inc., 555 Bryant Street #376 Palo Alto, CA, 94301 (650) 812-2614 Kenneth A, Clark Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road Palo Alto, CA, 94304 650-493-9300 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
07/30/2026 (Date of Event Which Requires Filing of This Statement) |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Catalyst4, Inc. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
20,906,689.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
47.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Robert Brown | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
20,906,689.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
47.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Ekemini Riley | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
20,906,689.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
47.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Mark Vorsatz | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
20,906,689.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
47.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, $0.0001 par value per share | |
| (b) | Name of Issuer:
MapLight Therapeutics, Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
800 Chesapeake Drive, Redwood City,
CALIFORNIA
, 94063. | |
Item 1 Comment:
This Amendment No 1 to the Schedule 13D filed by the undersigned on November 20, 2025, is hereby filed to update certain information with respect to the beneficial ownership of Voting Common Stock (the "Shares") of MapLight Therapeutics, Inc., a Delaware company (the "Issuer"), by Catalyst4, Inc. ("Catalyst"), Robert Brown, Ekemini Riley and Mark Vorsatz. The foregoing individuals, together with Catalyst, are collectively referred to as the "Reporting Persons." | ||
| Item 3. | Source and Amount of Funds or Other Consideration | |
Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following information:
During the last 60 days, the Reporting Persons acquired 1,209,225 Shares of the Issuer in multiple open market transactions for an aggregate purchase price of approximately $15.3 million, including commissions, as further disclosed in Item 5(c) of this Schedule 13D, which is incorporated by reference herein. The source of funds for the purchase of such Shares of the Issuer was the working capital of Catalyst. No part of the purchase price was represented by borrowed funds or other consideration obtained for the purpose of acquiring, holding, trading, or voting the securities, and there were no loans or financing arrangements involved in the transaction, with no other parties providing funds or consideration. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (c) | Item 5(c) of the Schedule 13D is hereby amended and supplemented by adding the following information:
The transactions by the Reporting Persons in the Shares of the Issuer during the past 60 days are set forth in Annex A to this Schedule 13D. This Amendment is being filed because the additional purchases effected by the Reporting Person subsequent to the Schedule 13D filed by the Reporting Person on November 20, 2025 (the "Prior Filing"), represent a material increase to the Reporting Person's ownership percentage of the Issuer's outstanding Shares. The transactions set forth in Annex A include the additional purchases of Shares effected by Catalyst subsequent to the Prior Filing, which are identified in Annex A. The Reporting Persons note that such additional purchases were previously disclosed on a Form 4 filed by Catalyst with the Securities and Exchange Commission on July 30, 2026. Except as otherwise disclosed herein, the Reporting Persons have not effected any transaction in the Shares in the last 60 days. | |
| Item 7. | Material to be Filed as Exhibits. | |
Annex A: Schedule of Transactions | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|